-
The diagnostic performance of fecal immunochemical tests for detecting advanced neoplasia at surveillance colonoscopy. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Grace Berwald, Graeme P. Young, Charles Cock, Peter Bampton, Robert Fraser, Erin L. Symonds
Background and Aims An increasing burden on healthcare resources has resulted in a backlog of individuals requiring colonoscopy, with delays in surveillance possibly detrimental for individuals at increased risk of colorectal cancer (CRC). This study investigated the use of a two-sample fecal immunochemical test (FIT to establish those most likely to have advanced neoplasia (AN) and in need of prioritized
-
The Index of Severity for Eosinophilic Esophagitis (I-SEE) Reflects Longitudinal Clinicopathologic Changes in Children Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Andrew Dickerson, Ayse Kolemen, Keeler Kime, Kira Chaiboonma, Ranjan Dohil, Glenn T. Furuta, Evan S. Dellon, Seema S. Aceves
Background and Aims The Index of Severity for EoE (I-SEE) was recently developed. We aimed to understand I-SEE scores in a longitudinal pediatric cohort and to determine the relationship between I-SEE and clinical features in children. Methods We performed a retrospective analysis on a prospectively enrolled cohort of children at a single center who were treated as part of routine clinical care. I-SEE
-
A Computer-Aided Detection (CADe) System Significantly Improves Polyp Detection in Routine Practice Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Rajesh N. Keswani, Urvi Thakkar, Alexandra Sals, John E. Pandolfino
Abstract not available
-
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER) Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Jean-Frederic Colombel, Ryan C. Ungaro, Bruce E. Sands, Corey A. Siegel, Douglas C. Wolf, John F. Valentine, Brian G. Feagan, Blue Neustifter, Harisha Kadali, Pradeep Nazarey, Alexandra James, Vipul Jairath, Rana M. Qasim Khan
BACKGROUND & AIMS Although biologics have revolutionized treatment of Crohn’s disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates. METHODS EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2,
-
An analysis of delayed bleeding in cases of colorectal endoscopic submucosal dissection due to types of direct oral anticoagulants in Japan Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Naohisa Yoshida, Yoshikazu Hayashi, Daichi Togo, Shiro Oka, Kazunori Takada, Shusei Fukunaga, Yoshinori Morita, Takemasa Hayashi, Kazuhiro Kozuka, Yosuke Tsuji, Takashi Murakami, Takeshi Yamamura, Yoriaki Komeda, Yoji Takeuchi, Kensuke Shinmura, Hiroko Fukuda, Shinji Yoshii, Shoko Ono, Shinichi Katsuki, Kazumasa Kawashima, Naoyuki Yamaguchi
-
In response to: Australasian insights and perspectives on the burden of Chronic Liver Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 James M. Paik, Linda Henry, Zobair M. Younossi
Abstract not available
-
A Rare Case of Esophageal Granular Cell Tumor in Eosinophilic Esophagitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Yousaf Abughofah, Grace E. Kim, Dennis Chen
Abstract not available
-
This Letter to the Editor is in response to: “Efficacy of Elimination Diets in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis”. Christoph Mayerhofer. Volume 21, Issue 9, P2197-2210, August 2023 Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 M.J. Warners, A.J. Bredenoord
Abstract not available
-
Reply to the Letter to the Editor: “Glucagon-like Peptide-1 Receptor Agonists: Best Choice for Patients with Cirrhosis and Diabetes?” Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Fu-Shun Yen, Teng-Shun Yu, Chih-Cheng Hsu, Chii-Min Hwu
Abstract not available
-
Development and Current State of Digital Therapeutics for Irritable Bowel Syndrome Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Darren M. Brenner, Amy M. Ladewski, Sarah Wimberly Kinsinger
Background Irritable bowel syndrome (IBS) is a common, debilitating disorder characterized by abdominal pain and disordered bowel habits. Current pharmacological treatments often provide incomplete symptom relief and may be poorly tolerated. Furthermore, alleviation of gastrointestinal symptoms does not always translate into improved quality of life (QOL) for IBS patients. Current treatment guidelines
-
Bioactive signaling lipids as drivers of chronic liver diseases J. Hepatol. (IF 25.7) Pub Date : 2023-09-21 Eleanna Kaffe, Annamaria Tisi, Christiana Magkrioti, Vassilis Aidinis, Wajahat Z. Mehal, Richard A. Flavell, Mauro Maccarrone
Lipids are important components for multiple cellular functions, and most have structural or energy storage roles. However, a small fraction of lipids exerts bioactive roles through binding to G protein coupled receptors (GPCRs) and induce a plethora of functions including cell proliferation, differentiation, growth, migration, apoptosis, senescence and survival. Bioactive signaling lipids are potent
-
Joint statement in support of hepatitis C human challenge studies Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-21 Harvey J Alter, Eleanor Barnes, Mia J Biondi, Andrea L Cox, Jake D Eberts, Jordan J Feld, T Jake Liang, Josh Morrison, Charles M Rice, Naglaa H Shoukry, David L Thomas, Jennifer Van Gennip, Charles Weijer
Abstract not available
-
-
Editorial Board Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Table of Contents Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Elsewhere in the AGA Journals Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Blue Notes Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21 Charles J. Kahi
Abstract not available
-
Parental Leave and Return-to-Work Policies: A Practical Model for Implementation in Gastroenterology Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21 Lauren D. Feld, Amy S. Oxentenko, Dawn Sears, Aline Charabaty, Loren G. Rabinowitz, Julie K. Silver
Abstract not available
-
Exam 1: Tools to Measure the Impact of Structural Racism and Discrimination on Gastrointestinal and Hepatology Disease Outcomes: A Scoping Review Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Exam 2: Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
-
Endoscopic procedures in HEPATOLOGY:CURRENT trends and new developments J. Hepatol. (IF 25.7) Pub Date : 2023-09-18 Wim Laleman, Emma Vanderschueren, Zain Seyad Mehdi, Reiner Wiest, Andres Cardenas, Jonel Trebicka
Gastrointestinal endoscopy has always formed a reliable and indispensable backbone in the diagnosis and management of hepatobilary disorders and their complications. However, with evolving non-invasive testing, personalized medicine has reframed the utility and necessity of endoscopical screening. Conversely, the growing interest and use of endoscopic ultrasound and advanced endoscopy within gastrointestinal
-
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-18 John V Reynolds, Shaun R Preston, Brian O'Neill, Maeve A Lowery, Lene Baeksgaard, Thomas Crosby, Moya Cunningham, Sinead Cuffe, Gareth O Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, George B Hanna, Frederick R Bartlett, Alberto Alvarez-Iglesias, Michael P Achiam, Magnus Nilsson, Guillaume Piessen, Narayanasamy Ravi, Jacintha O'Sullivan
Background The optimum curative approach to adenocarcinoma of the oesophagus and oesophagogastric junction is unknown. We aimed to compare trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen]) with optimum contemporaneous perioperative chemotherapy regimens (epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine [a modified MAGIC regimen]
-
CROSS versus modified MAGIC or FLOT in oesophageal and gastro-oesophageal junction adenocarcinoma Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2023-09-18 Peter S N van Rossum, Hanneke W M van Laarhoven
Abstract not available
-
Global Prevalence of Fecal Incontinence in Community-Dwelling Adults: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Isabelle Mack, Heiko Hahn, Celina Gödel, Paul Enck, Adil E. Bharucha
-
Sex differences in treatment response to nucleos(t)ide therapy in chronic hepatitis B: a multicenter longitudinal study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Angela Chau, Ming-Lun Yeh, Pei-Chien Tsai, Daniel Q. Huang, Sung Eun Kim, Huy Trinh, Eileen L. Yoon, Hyunwoo Oh, Jae Yoon Jeong, Sang Bong Ahn, Jihyun An, Cheng-Hao Tseng, Yao-Chun Hsu, Soung Won Jeong, Yong Kyun Cho, Jae-Jun Shim, Hyoung Su Kim, Takanori Ito, Sebastián Marciano, Keigo Kawashima, Mindie H. Nguyen
Background It is unclear if there may be sex differences in response to nucleos(t)ide analogs (NA) including viral suppression [VR], biochemical response [BR], complete response [CR], and HCC incidence among hepatitis B patients. We compared NA treatment outcomes by sex. Approach A retrospective cohort study of 3388 treatment-naïve adult hepatitis B patients (1250 female; 2138 male) from the REAL-B
-
Long-term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data over Eight Years from the Hong Kong FMT Registry Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Yuk Kam Yau, Louis Ho Shing Lau, Rashid Nok Shun Lui, Sunny Hei Wong, Cosmos Liutao Guo, Joyce Wing Yan Mak, Jessica Yuet Ling Ching, Margaret Ip, Michael A. Kamm, David T. Rubin, Paul Kay Sheung Chan, Francis Ka Leung Chan, Siew Chien Ng
-
HLADQA1*05G>A genetic-screening promotes the safe delivery of combination therapy in inflammatory bowel disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Aze Wilson, Nilesh Chande, Terry Ponich, James C. Gregor, Yun-hee Choi, Richard B. Kim
Abstract not available
-
The Grim Side of Microscopic Colitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-18 Ayokunle T. Abegunde
Abstract not available
-
Hemosuccus pancreaticus caused by splenic artery pseudoaneurysm: Two cases diagnosed and treated with EUS Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-18 Mehdi Mohamadnejad, Ali Ali Asgari, Mohammad Al-Haddad
Abstract not available
-
Malignant IPMN with underlying annular pancreas Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-18 Seung-Ho Sin, Hyung-Keun Kim, Huin-Suk Chae
Abstract not available
-
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B J. Hepatol. (IF 25.7) Pub Date : 2023-09-19 Ho Soo Chun, George V. Papatheodoridis, Minjong Lee, Hye Ah Lee, Yeong Hwa Kim, Seo Hyun Kim, Yun-Seo Oh, Su Jin Park, Jihye Kim, Han Ah Lee, Hwi Young Kim, Tae Hun Kim, Eileen L. Yoon, Dae Won Jun, Sang Hoon Ahn, Vana Sypsa, Cihan Yurdaydin, Pietro Lampertico, Jose Luis Calleja, Harry LA. Janssen, Yoon Jun Kim
-
Are we ready to translate metabolomics into clinical practice for ACLF prediction and diagnosis? J. Hepatol. (IF 25.7) Pub Date : 2023-09-19 Bryan D. Badal, I Jane Cox, Jasmohan S. Bajaj
Abstract not available
-
Endocrine aspects of metabolic dysfunction associated steatotic liver disease (MASLD): Beyond insulin resistance J. Hepatol. (IF 25.7) Pub Date : 2023-09-18 Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, Michael Charlton
While the links between metabolic dysfunction associated steatotic liver disease liver disease (MASLD) and obesity, insulin resistance are widely appreciated, there are a host of complex interactions between the liver and other endocrine axes. While it can be difficult to definitively distinguish direct causal relationships and those attributable to increased adipocyte mass, there is substantial evidence
-
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2023-09-18 Caitlin C. Murphy, Timothy A. Zaki
-
PREVALENCE AND PREDICTORS OF BARRETT’S ESOPHAGUS AFTER NEGATIVE INITIAL ENDOSCOPY: ANALYSIS FROM TWO NATIONAL DATABASES Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Lovekirat Dhaliwal, Amrit K. Kamboj, J. Lucas Williams, Apoorva K. Chandar, Karan Sachdeva, Erin Gibbons, Ramona Lansing, Melissa Passe, Jamie A. Perez, Katelin L.R. Avenir, Scott A. Martin, Cadman L. Leggett, Amitabh Chak, Gary W. Falk, Sachin Wani, Nicholas J. Shaheen, John B. Kisiel, Prasad G. Iyer
Introduction Guidelines suggest a single screening esophagogastroduodenoscopy (EGD) in patients with multiple risk factors for Barrett’s esophagus (BE). We aimed to determine BE prevalence and predictors on repeat EGD after a negative initial EGD, using two large national databases (GI Quality Improvement Consortium [GIQuIC] and TriNetX). Methods Patients who underwent at least 2 EGDs were included
-
Alpha-1 antitrypsin (AAT) augmentation and the liver phenotype of adults with AAT deficiency (genotype Pi*ZZ) Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Malin Fromme, Karim Hamesch, Carolin V. Schneider, Mattias Mandorfer, Monica Pons, Katrine Thorhauge, Vitor Pereira, Jan Sperl, Sona Frankova, Matthias C. Reichert, Federica Benini, Barbara Burbaum, Moritz Kleinjans, Samira Amzou, Laura Rademacher, Lisa Bewersdorf, Jef Verbeek, Frederik Nevens, Joan Genesca, Marc Miravitlles, Pavel Strnad
Background and aims Alpha-1 antitrypsin (AAT) is a major protease inhibitor produced by hepatocytes. The most relevant AAT mutation giving rise to AAT deficiency (AATD), the ‘Pi*Z’ variant, causes harmful AAT protein accumulation in the liver, shortage of AAT in the systemic circulation and thereby predisposes to liver and lung injury. Although intravenous AAT augmentation constitutes an established
-
Accuracy, reliability and comprehensiveness of ChatGPT generated medical responses for patients with NAFLD Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Nicola Pugliese, Vincent Wai-Sun Wong, Jörn M. Schattenberg, Manuel Romero-Gomez, Giada Sebastiani, , Alessio Aghemo
Abstract not available
-
Withdrawal of Immunomodulators or TNF Antagonists in Patients with Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 David J. Katibian, Virginia Solitano, D. Brent Polk, Tran Nguyen, Christopher Ma, Gaurav Syal, Taku Kobayashi, Toshifumi Hibi, Sine Buhl, Mark Andrew Ainsworth, Vipul Jairath, Siddharth Singh
-
Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Peter Ueda, Viktor Wintzell, Mads Melbye, Björn Eliasson, Jonas Söderling, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Henrik Svanström, Anders Hviid, Björn Pasternak
-
Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Diana L. Snyder, Evan S. Dellon
Abstract not available
-
Endoscopic resection of cecal neoplasia with full-thickness resection of the appendiceal stump using double-layered suturing Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-14 Daiki Kitagawa, Shunsuke Yoshii, Ryu Ishihara
Abstract not available
-
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma with Varices using Red Dichromatic Imaging Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-14 Tomoya Ueda, Takashi Kanesaka, Ryu Ishihara
Abstract not available
-
Corrigendum to “EASL clinical practice guidelines on the management of cystic liver diseases” [J Hepatol (77) 1083–1108] J. Hepatol. (IF 25.7) Pub Date : 2023-09-17
Abstract not available
-
Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis – a propensity-score matched intention-to-treat analysis J. Hepatol. (IF 25.7) Pub Date : 2023-09-16 Fredrik Åberg, Ville Sallinen, Samuli Tuominen, René Adam, Vincent Karam, Darius Mirza, Michael A. Heneghan, Pål-Dag Line, William Bennet, Bo-Göran Ericzon, Michal Grat, Peter Lodge, Allan Rasmussen, Moritz Schmelzle, Douglas Thorburn, Constantino Fondevila, Ilkka Helanterä, Arno Nordin
-
Let’s unite Hepatology! Become an EASL member today and discover your benefits J. Hepatol. (IF 25.7) Pub Date : 2023-09-14
Abstract not available
-
-
Nutrients associated with metabolic dysfunction-associated steatotic liver disease J. Hepatol. (IF 25.7) Pub Date : 2023-09-16 Seogsong Jeong
Abstract not available
-
Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition? J. Hepatol. (IF 25.7) Pub Date : 2023-09-16 Narendra Singh Choudhary, Swapnil Dhampalwar, Neeraj Saraf, Arvinder S. Soin
Abstract not available
-
Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause/Cause-Specific Mortality among Adults in the United States J. Hepatol. (IF 25.7) Pub Date : 2023-09-16 Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Abstract not available
-
In-situ or Ex-situ Split: Does it all Come Down to Static Cold Storage? J. Hepatol. (IF 25.7) Pub Date : 2023-09-16 Xavier Muller, Guillaume Rossignol, Natacha Boulanger, Kayvan Mohkam, Jean-Yves Mabrut
Abstract not available
-
Further comments on the changing role of donor warm ischemia time in DCD liver selection in the era of machine perfusion J. Hepatol. (IF 25.7) Pub Date : 2023-09-15 Riccardo De Carlis, Andrea Lauterio, Davide Bernasconi, Burcin Taner
Abstract not available
-
-
Sign up to EASL Campus: your open-access eLearning Hub J. Hepatol. (IF 25.7) Pub Date : 2023-09-14
Abstract not available
-
EASL Studio is streaming live every week and bringing you hepatology news, from every angle J. Hepatol. (IF 25.7) Pub Date : 2023-09-14
Abstract not available
-
EASL is supporting five major EU-funded projects on the liver. Discover them! J. Hepatol. (IF 25.7) Pub Date : 2023-09-14
Abstract not available
-
-
From the Editor’s Desk... J. Hepatol. (IF 25.7) Pub Date : 2023-09-14 Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli
Abstract not available
-
Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals J. Hepatol. (IF 25.7) Pub Date : 2023-09-14 Tatsuya Minami, Masaya Sato, Hidenori Toyoda, Satoshi Yasuda, Tomoharu Yamada, Takuma Nakatsuka, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Masashi Izumiya, Yasuo Tanaka, Motoyuki Otsuka, Takamasa Ohki, Masahiro Arai, Yoshinari Asaoka, Atsushi Tanaka, Kiyomi Yasuda, Hideaki Miura, Itsuro Ogata, Toshiro Kamoshida, Ryosuke Tateishi
-
Retraction notice to “Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy” [J Hepatol 62 (3) (2015) 647–656] J. Hepatol. (IF 25.7) Pub Date : 2023-09-14 Rui Guo, Xihui Xu, Sara A. Babcock, Yingmei Zhang, Jun Ren
Abstract not available
更新日期：2023-09-23
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号